Table 5.

The Top 10 co-cited references in BC immunotherapy research.

Rank	Co-cited reference	Journal	Author	Year	Citations
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial	The Lancet	Rosenberg JE et al.	2016	503
2	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma	The New England journal of medicine	Bellmunt J et al.	2017	428
3	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial	The Lancet	Balar AV et al.	2017	316
4	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial	Lancet Oncology	Sharma P et al.	2017	306
5	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer	Nature	Powles T et al.	2014	281
6	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial	The Lancet	Powles T et al.	2018	261
7	EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016	European Urology	Babjuk M et al.	2017	258
8	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer	Journal of Clinical Oncology	Massard C et al.	2016	208
9	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study	The Lancet	Balar AV et al.	2017	205
10	EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016	Cell	Robertson AG et al.	2017	191